Deborah_Hall,
In answer to your question about SGLT-2s and bone remodeling I asked ChatGPT. Keep in mind that you can not have complete trust in this particular AI program which regularly gives me wacky answers. Here is my question, followed by ChatGPT’s answer:
SGLT-2 drugs can cause problems with bone remodeling: Search for evidence of this for each type of SGLT-2 drug. Note whether evidence indicates an increase or a decrease in bone density for each SGLT-2 type. Note whether there could be an increase or decrease in fracture risk due to bone remodeling for each SGLT-2 type. Put data in a table and use the minimum number of words to clearly answer each point.
Evidence is strongest for canagliflozin; for the other SGLT-2 inhibitors, bone effects are generally neutral or uncertain. Class-level meta-analyses show no significant reduction in BMD and no significant increase in fracture risk overall.
| SGLT-2 drug | Bone remodeling / BMD evidence | BMD direction | Fracture risk from bone effects |
|---|---|---|---|
| Canagliflozin | Most evidence for altered mineral metabolism; some long-term studies reported modest hip BMD loss. CANVAS fracture signal observed. | ↓ slight (hip; not consistently all sites) | Possible ↑; evidence mixed, not confirmed in later meta-analyses. |
| Dapagliflozin | Studies generally found no effect on bone turnover markers or BMD. | ↔ no meaningful change | ↔ no clear increase; isolated renal-impairment trial reported more fractures. |
| Empagliflozin | Clinical trials and pooled analyses found no meaningful BMD or fracture signal. | ↔ no meaningful change | ↔ no increase detected. |
| Ertugliflozin | Limited data; cardiovascular outcomes trial found no significant fracture increase. | ↔/unknown | ↔ no increase detected. |
| Sotagliflozin | Very limited direct bone-remodeling data. | Unknown | Unknown; no established signal. |
| Drug | Bottom-line assessment |
|---|---|
| Canagliflozin | Weak evidence for ↓ BMD and possible ↑ fracture risk; strongest concern in class. |
| Dapagliflozin | Neutral BMD; fracture risk generally neutral. |
| Empagliflozin | Neutral BMD; fracture risk neutral. |
| Ertugliflozin | Neutral/insufficient BMD data; fracture risk neutral. |
| Sotagliflozin | Insufficient evidence. |
Overall class conclusion: SGLT-2 inhibitors do not appear to decrease BMD or increase fracture risk as a class; concern is mainly limited to canagliflozin, and even that signal remains debated.
